$120M
The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.
C
CellCentric
CellCentric develops novel oral targeted therapies to treat resistant blood cancers.
United Kingdom—Founded 2003
$120MTotal raised
CellCentric is a clinical-stage biotechnology company developing oral targeted treatments for cancer, with a primary focus on multiple myeloma.
Categories
Team
AS
Azim Surani
Founder
Will West
CEO
Will brings biotech operating and investment experience, currently serving as chief executive of CellCentric and investment advisor at Morningside alongside several non-executive roles.
LinkedIn